Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more
Genmab A/S (GNMSF) - Total Assets
Latest total assets as of September 2025: $7.02 Billion USD
Based on the latest financial reports, Genmab A/S (GNMSF) holds total assets worth $7.02 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genmab A/S - Total Assets Trend (2002–2024)
This chart illustrates how Genmab A/S’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genmab A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
Genmab A/S's total assets of $7.02 Billion consist of 60.8% current assets and 39.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.5% |
| Accounts Receivable | $6.69 Billion | 14.6% |
| Inventory | $62.00 Million | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $12.34 Billion | 26.9% |
| Goodwill | $2.54 Billion | 5.5% |
Asset Composition Trend (2002–2024)
This chart illustrates how Genmab A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genmab A/S's current assets represent 60.8% of total assets in 2024, a decrease from 89.6% in 2002.
- Cash Position: Cash and equivalents constituted 21.5% of total assets in 2024, up from 16.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 4.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 26.9% of total assets.
Genmab A/S Competitors by Total Assets
Key competitors of Genmab A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Genmab A/S - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Genmab A/S generates 0.47x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Genmab A/S generates $ 17.12 in net profit.
Genmab A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.03 | 5.17 | 15.00 |
| Quick Ratio | 6.01 | 5.15 | 15.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.73 Billion | $ 19.11 Billion | $ 17.54 Billion |
Genmab A/S - Advanced Valuation Insights
This section examines the relationship between Genmab A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.21 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 29.8% |
| Total Assets | $45.81 Billion |
| Market Capitalization | $11.33 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Genmab A/S's assets below their book value (0.25 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Genmab A/S's assets grew by 29.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Genmab A/S (2002–2024)
The table below shows the annual total assets of Genmab A/S from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $45.81 Billion | +29.82% |
| 2023-12-31 | $35.29 Billion | +17.17% |
| 2022-12-31 | $30.12 Billion | +22.30% |
| 2021-12-31 | $24.63 Billion | +16.48% |
| 2020-12-31 | $21.14 Billion | +39.61% |
| 2019-12-31 | $15.14 Billion | +78.99% |
| 2018-12-31 | $8.46 Billion | +28.14% |
| 2017-12-31 | $6.60 Billion | +26.05% |
| 2016-12-31 | $5.24 Billion | +34.23% |
| 2015-12-31 | $3.90 Billion | +36.13% |
| 2014-12-31 | $2.87 Billion | +65.56% |
| 2013-12-31 | $1.73 Billion | +2.28% |
| 2012-12-31 | $1.69 Billion | +8.21% |
| 2011-12-31 | $1.56 Billion | -36.96% |
| 2010-12-31 | $2.48 Billion | +11.71% |
| 2009-12-31 | $2.22 Billion | -31.83% |
| 2008-12-31 | $3.26 Billion | -17.68% |
| 2007-12-31 | $3.96 Billion | +119.37% |
| 2006-12-31 | $1.80 Billion | +31.68% |
| 2005-12-31 | $1.37 Billion | +7.75% |
| 2004-12-31 | $1.27 Billion | +7.78% |
| 2003-12-31 | $1.18 Billion | -25.46% |
| 2002-12-31 | $1.58 Billion | -- |